Profectus BioSciences, Inc.: Series C $19M

Posted in I - Series C, Q - 3Q09, R - MID ATLANTIC, X - Vaccines, X - Virology, XX - MD

Profectus BioSciences (Baltimore, MD) a clinical-stage biopharmaceutical focused on the development of vaccines for chronic viral infections, closed a $5M Series C financing. Participants include Cross Atlantic Capital Partners.

Aug

2009

Avila Therapeutics, Inc.: Series B $30M

Posted in I - Series B, Q - 3Q09, R - NORTH EAST, X - Autoimmune, X - Oncology, X - Therapeutic Platform, X - Virology, XX - MA

Avila Therapeutics (Waltham, MA) a preclinical-stage biopharmaceutical company focused on protein silencing drugs for viral infections, cancer and autoimmune diseases, closed a $30M Series B financing. Participants include Novartis Option Fund, Abingworth Management, Advent Venture Partners, Atlas Venture and Polaris Venture Partners.

Dec

2008

Cocrystal Discovery, Inc.: Series A $10M

Posted in I - Series A, Q - 3Q08, R - NORTH WEST, X - Virology

Cocrystal Discovery (Seattle, WA) developer of antiviral therapeutics for the treatment of serious and chronic viral diseases, closed a $10M Series A financing. Participants include The Frost Group.

Dec

2008

Jennerex, Inc.: Series B $8.3M

Posted in I - Series B, Q - 3Q08, R - WEST, X - Oncology, X - Virology

Jennerex (San Francisco, CA) clinical-stage biopharmaceutical company developing a class of targeted oncolytic virus therapeutics, closed an $8.3M Series B financing. Participants include ?

to top of page...